Get our newsletter delivered directly to your inbox
I have already subscribed | Do not show this message again
Your email has been successfully registered.
The pharmaceutical company Laboratorios de Biológicos y Reactivos de México (Birmex) produced a test batch of the Russian vaccine Sputnik V against COVID-19, the Russian Direct Investment Fund (RDIF) informed on Monday.
The institution noted that Mexico thus becomes the first North American country to register the Russian drug, start its local production and thus be able to accelerate its national vaccination program.
Kirill Dmitriev, executive director of RDIF, commented that the production of the test batch in Mexico is an important step in the technology transfer process: "We hope that the batch will meet the most stringent requirements," he stressed.
"The Russian Direct Investment Fund and Mexican company @Birmex produced a test batch of #SputnikV vaccine. #Mexico has become the first country in North America to both register and launch local production of the @sputnikvaccine."
Data obtained by regulators during immunization in several nations, including Mexico, Argentina, Serbia, Bahrain, Hungary, United Arab Emirates and others, demonstrate that the Russian vaccine is among the safest and most effective against the SARS-CoV-2 coronavirus.
Sputnik V is based on a proven platform of human adenoviral vectors and uses two different vectors for the two injections in one vaccination course.
Its developers at the Gamaleya Center point out that this feature provides a longer period of immunity than vaccines that use the same delivery mechanism for both injections.